Objectives: To test the hypothesis of a relationship between a specific genetic lesion (T2:ERG) and imaging scores, such as PI-RADS and PRI-MUS, and to test the effectiveness of these parameters for the diagnosis of prostate cancer (PCa) and clinically significant PCa (csPCa). Materials and methods: This is a prospective study of men with suspected PCa enrolled between 2016 and 2019 at a high-volume tertiary hospital. Patients underwent systematic US-guided biopsy, plus targeted biopsy if they were presenting with >=1 suspicious lesion (PI-RADS>2) at mpMRI or PR-IMUS >2 at micro-ultrasound assessment. For each patient, one core from the highest PI-RADS or PRI-MUS lesion was collected for T2:ERG analysis. Multivariable logistic regression models (LRMs) were fitted for csPCa with a clinical model (age, total PSA, previous biopsy, family history for PCa), a clinical plus PI-RADS, clinical plus T2:ERG, clinical plus PI-RADS plus T2:ERG, and T2:ERG plus PI-RADS alone. Results: The cohort consists of 158 patients: 83.5% and 66.2% had respectively a diagnosis of PCa and csPCa after biopsy. A T2:ERG fusion was found in 37 men and 97.3% of these patients harbored PCa, while 81.1% were diagnosed with csPCa. SE of T2:ERG assay for csPCa was 28.8%, SP 87.0%, NPV 38.8%, and PPV 81.1%. Of 105 patients who performed mpMRI 93.% had PIRADS ≥3. SE of mpMRI for csPCa was 98.5%, SP was 12.8%, NPV was 83.3%, and PPV was 65.7%. Among 67 patients who were subjected to micro-US, 90% had a PRI-MUS ≥3. SE of micro-US for csPCa was 89.1%, SP was 9.52%, NPV was 28.6%, and PPV was 68.3%. At univariable LRM T2:ERG was confirmed as independent of mpMRI and micro-US result (OR 1.49, p=0.133 and OR 1.82, p=0.592, respectively). At multivariable LRM the clinical model alone had an AUC for csPCa of 0.74 while the clinical model including PI-RADS and T2:ERG achieved an AUC of 0.83. Conclusions: T2:ERG translocation and imaging results are independent of each other, but both are related csPCa. To evaluate the best diagnostic work-up for PCa and csPCa detection, all available tools (T2:ERG detection and imaging techniques) should be employed together as they appear to have a complementary role.
Objectives: To test the hypothesis of a relationship between a specific genetic lesion (T2:ERG) and imaging scores, such as PI-RADS and PRI-MUS, and to test the effectiveness of these parameters for the diagnosis of prostate cancer (PCa) and clinically significant PCa (csPCa). Materials and methods: This is a prospective study of men with suspected PCa enrolled between 2016 and 2019 at a high-volume tertiary hospital. Patients underwent systematic US-guided biopsy, plus targeted biopsy if they were presenting with >=1 suspicious lesion (PI-RADS>2) at mpMRI or PR-IMUS >2 at micro-ultrasound assessment. For each patient, one core from the highest PI-RADS or PRI-MUS lesion was collected for T2:ERG analysis. Multivariable logistic regression models (LRMs) were fitted for csPCa with a clinical model (age, total PSA, previous biopsy, family history for PCa), a clinical plus PI-RADS, clinical plus T2:ERG, clinical plus PI-RADS plus T2:ERG, and T2:ERG plus PI-RADS alone. Results: The cohort consists of 158 patients: 83.5% and 66.2% had respectively a diagnosis of PCa and csPCa after biopsy. A T2:ERG fusion was found in 37 men and 97.3% of these patients harbored PCa, while 81.1% were diagnosed with csPCa. SE of T2:ERG assay for csPCa was 28.8%, SP 87.0%, NPV 38.8%, and PPV 81.1%. Of 105 patients who performed mpMRI 93.% had PIRADS ≥3. SE of mpMRI for csPCa was 98.5%, SP was 12.8%, NPV was 83.3%, and PPV was 65.7%. Among 67 patients who were subjected to micro-US, 90% had a PRI-MUS ≥3. SE of micro-US for csPCa was 89.1%, SP was 9.52%, NPV was 28.6%, and PPV was 68.3%. At univariable LRM T2:ERG was confirmed as independent of mpMRI and micro-US result (OR 1.49, p=0.133 and OR 1.82, p=0.592, respectively). At multivariable LRM the clinical model alone had an AUC for csPCa of 0.74 while the clinical model including PI-RADS and T2:ERG achieved an AUC of 0.83. Conclusions: T2:ERG translocation and imaging results are independent of each other, but both are related csPCa. To evaluate the best diagnostic work-up for PCa and csPCa detection, all available tools (T2:ERG detection and imaging techniques) should be employed together as they appear to have a complementary role.
Authors: Matthew R Cooperberg; Peter R Carroll; Marc A Dall'Era; Benjamin J Davies; John W Davis; Scott E Eggener; Felix Y Feng; Daniel W Lin; Todd M Morgan; Alicia K Morgans; Daniel E Spratt; Samir S Taneja; David F Penson Journal: Eur Urol Date: 2019-05-23 Impact factor: 20.096
Authors: Giovanni Lughezzani; Alberto Saita; Massimo Lazzeri; Marco Paciotti; Davide Maffei; Giuliana Lista; Rodolfo Hurle; Nicolò Maria Buffi; Giorgio Guazzoni; Paolo Casale Journal: Eur Urol Oncol Date: 2018-10-25
Authors: Kyung Park; James T Dalton; Ramesh Narayanan; Christopher E Barbieri; Michael L Hancock; David G Bostwick; Mitchell S Steiner; Mark A Rubin Journal: J Clin Oncol Date: 2013-12-02 Impact factor: 44.544
Authors: Martina Maggi; Janet E Cowan; Vittorio Fasulo; Samuel L Washington; Peter E Lonergan; Alessandro Sciarra; Hao G Nguyen; Peter R Carroll Journal: J Urol Date: 2020-11-06 Impact factor: 7.450
Authors: Claire M de la Calle; Vittorio Fasulo; Janet E Cowan; Peter E Lonergan; Martina Maggi; Adam J Gadzinski; Reuben Au Yeung; Alberto Saita; Matthew R Cooperberg; Katsuto Shinohara; Peter R Carroll; Hao G Nguyen Journal: J Urol Date: 2020-09-08 Impact factor: 7.450
Authors: Carissa E Chu; Janet E Cowan; Peter E Lonergan; Samuel L Washington; Vittorio Fasulo; Claire M de la Calle; Katsuto Shinohara; Antonio C Westphalen; Peter R Carroll Journal: Eur Urol Oncol Date: 2021-01-19
Authors: Elizabeth K Bancroft; Elizabeth C Page; Mark N Brook; Sarah Thomas; Natalie Taylor; Jennifer Pope; Jana McHugh; Ann-Britt Jones; Questa Karlsson; Susan Merson; Kai Ren Ong; Jonathan Hoffman; Camilla Huber; Lovise Maehle; Eli Marie Grindedal; Astrid Stormorken; D Gareth Evans; Jeanette Rothwell; Fiona Lalloo; Angela F Brady; Marion Bartlett; Katie Snape; Helen Hanson; Paul James; Joanne McKinley; Lyon Mascarenhas; Sapna Syngal; Chinedu Ukaegbu; Lucy Side; Tessy Thomas; Julian Barwell; Manuel R Teixeira; Louise Izatt; Mohnish Suri; Finlay A Macrae; Nicola Poplawski; Rakefet Chen-Shtoyerman; Munaza Ahmed; Hannah Musgrave; Nicola Nicolai; Lynn Greenhalgh; Carole Brewer; Nicholas Pachter; Allan D Spigelman; Ashraf Azzabi; Brian T Helfand; Dorothy Halliday; Saundra Buys; Teresa Ramon Y Cajal; Alan Donaldson; Kathleen A Cooney; Marion Harris; John McGrath; Rosemarie Davidson; Amy Taylor; Peter Cooke; Kathryn Myhill; Matthew Hogben; Neil K Aaronson; Audrey Ardern-Jones; Chris H Bangma; Elena Castro; David Dearnaley; Alexander Dias; Tim Dudderidge; Diana M Eccles; Kate Green; Jorunn Eyfjord; Alison Falconer; Christopher S Foster; Henrik Gronberg; Freddie C Hamdy; Oskar Johannsson; Vincent Khoo; Hans Lilja; Geoffrey J Lindeman; Jan Lubinski; Karol Axcrona; Christos Mikropoulos; Anita V Mitra; Clare Moynihan; Holly Ni Raghallaigh; Gad Rennert; Rebecca Collier; Judith Offman; Zsofia Kote-Jarai; Rosalind A Eeles Journal: Lancet Oncol Date: 2021-10-19 Impact factor: 54.433